<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01220206</url>
  </required_header>
  <id_info>
    <org_study_id>POM 2010-003</org_study_id>
    <nct_id>NCT01220206</nct_id>
  </id_info>
  <brief_title>POMx In the Treatment of Erectile Dysfunction</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Trial to Evaluate the Safety and Efficacy of POM Wonderful Pomegranate Extract Capsules In Male Subjects With Moderate to Severe Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>POM Wonderful LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Target Health Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>POM Wonderful LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      POMx can be used as a treatment for erectile dysfunction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects on ED</measure>
    <time_frame>Basedline to end of study</time_frame>
    <description>There are three co-primary endpoints: Erectile Function domain score (questions 1-5 and 15 of the IIEF), and questions 2 and 3 on the SEP diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on ED</measure>
    <time_frame>baseline to end of study</time_frame>
    <description>Secondary efficacy variables are: Total score on SEP and domains of the IIEF representing intercourse satisfaction (questions 6-8), orgasmic function (questions 9-10), and overall satisfaction (questions 11-12) and a Global Assessment Questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 placebo capsules daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>one POMx capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One POMx capsule, one placebo capsule daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 POMx Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 POMx Capsules daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 placebo capsules daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>One POMx capsule daily</intervention_name>
    <description>One POMx capsule, one placebo capsule daily</description>
    <arm_group_label>one POMx capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 POMx Capsules</intervention_name>
    <description>2 POMx Capsules daily</description>
    <arm_group_label>2 POMx Capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male 21 to 70 years old

          -  Erectile Function domain score of 10-19 on the International Index of Erectile
             Function (IIEF)

          -  In a stable, monogamous relationship with a consenting female partner and willing to
             attempt vaginal sexual intercourse on at least one occasion per week on average during
             each study period

          -  History of ED (clinically defined as the inability to attain and maintain an erection
             of the penis sufficient to permit satisfactory sexual intercourse) of at least 3
             months duration

          -  Treated previously with a PDE-5 inhibitor with a satisfactory response, as defined by
             the patient.

          -  Signed informed consent

        Exclusion Criteria:

        -The presence of any of the following excludes a subject from study enrollment: ED caused
        by untreated endocrine disease, i.e., hypopituitarism, hypothyroidism, hypogonadism

          -  A diagnosis of situational psychogenic ED

          -  Significant penile pathology, including but not limited to curvature, fibrosis,
             sexually transmitted disease, and penile implant

          -  Clinically significant hepatic, renal, neurological disease, diabetes mellitus, spinal
             cord injury, significant coronary heart disease, significant neurological disease or
             hepatitis B and/or C

          -  History of prostate cancer or prostate surgery other than a transurethral resection of
             the prostate

          -  History of alcoholism within the previous 2 years

          -  Current consumer of three or more units of alcohol per day (1 unit is equivalent to 1
             glass of wine, 1 pint of beer, or 1 shot of hard liquor)

          -  Taking ED therapy (prescription medications, over-the-counter medications, herbal
             preparations or medical devices) after the screening visit

          -  Participation in another study with an investigational drug or device during the 30
             days prior to study entry

          -  Has a condition interfering with his ability to provide informed consent or comply
             with study instructions
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James McMurray, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Affiliated Research Center, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Affiliated Research Center</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2010</study_first_submitted>
  <study_first_submitted_qc>October 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2010</study_first_posted>
  <last_update_submitted>October 4, 2012</last_update_submitted>
  <last_update_submitted_qc>October 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ED</keyword>
  <keyword>POMx</keyword>
  <keyword>Pomegranate</keyword>
  <keyword>Erectile dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

